This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
The Department of the Army Medical Command awarded a $161,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Deciphering Translational Control of Androgen Receptor in Prostate Cancer". The grant project will run from April 1, 2024 to March 31, 2026. As a leading academic medical center and research institution, UCSF has extensive expertise in federal...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,453,501.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) on June 1, 2024. The grant supports the development of "Targeted Theranostic Nanopolymers for Imaging and Alpha Radiopharmaceutical Therapy of Prostate Cancer" over a period of 3 years through May 31, 2027. As a leading academic medical center, UCSF will leverage its expertise in biomedical...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
This $993,283 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of California, San Francisco (UCSF) aimed at transforming healthcare for military service members, veterans, and the broader public. The 2-year award, effective from September 1, 2025 to August 31, 2027, will fund proteomic research to investigate determinants and components of disease progression in multiple...
This federal Project Grant award of $1,041,595.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) on September 1, 2024. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, this 3-year Melanoma Research Program Team Science Award will fund innovative and...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...
The University of California, San Francisco (UCSF) has been awarded a $1,202,087 federal Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to investigate SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer. The award, effective July 1, 2024 through June 30, 2028, will enable UCSF researchers to conduct innovative scientific studies to develop new treatments for this challenging disease. As a leading academic...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
This federal Project Grant award of $999,999.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research into cell-free DNA epigenetic biomarkers for multiple sclerosis. The award was granted on August 1, 2025 to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution. The project aims to transform healthcare for military service...